Company also reports preliminary unaudited 2024 revenue of $701.0 millionPARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver ...
I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head,” said Michael Rossi, President and Chief Executive Officer. “We believe Doug’s extensive experience leading ...
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...
Ice has been a mainstay at sporting events for decades. As a standard treatment for twisted ankles, jammed fingers and sprained knees, you will often see bags and buckets of ice ready to be employed ...
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomica ...